HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Nonerosive lichen planus of oral mucosa — Clinical Guidelines

Overview

Nonerosive lichen planus of the oral mucosa is a chronic inflammatory condition characterized by immune-mediated destruction of the oral epithelium without significant erosion or ulceration. It often presents as white striae or plaques but can also manifest as atrophic or erosive lesions 4.

Diagnosis

Clinical examination focusing on characteristic white, lacy lesions or atrophic areas 4.

Histopathological examination showing typical interface lymphocytic infiltration 4.

Direct immunofluorescence may be useful but is not routinely required 4.

Variability in diagnosis noted among pathologists, highlighting the need for standardized criteria 5.

Management

First-line treatments: Topical corticosteroids (e.g., fluocinonide) are commonly used 2.

Adjunctive therapies: Platelet concentrates show no significant difference in efficacy compared to topical corticosteroids for symptom relief 2.

Consider vitamin supplementation: Although not definitively supported by significant differences in serum levels, monitoring and supplementation of vitamins (A, B12, C, D3, E) may be considered 3.

Special Populations

Comorbidities: Patients with oral lichen planus (OLP) have a higher prevalence of hypertension, suggesting cardiovascular monitoring 1.

Medication considerations: OLP patients frequently use medications metabolized by polymorphic cytochrome P450 enzymes, particularly those with potential for poor metabolism (PM) risk 8.

Key Recommendations

Regularly screen for hypertension in patients with nonerosive oral lichen planus due to increased prevalence 1 (Evidence: Moderate).

Initiate treatment with topical corticosteroids for symptom management in nonerosive lichen planus 2 (Evidence: Moderate).

Consider monitoring vitamin levels, though routine supplementation is not strongly supported by current evidence 3 (Evidence: Weak).

Evaluate medication profiles, focusing on drugs metabolized by CYP2D6 and CYP2C19, given potential associations with OLP 6 8 (Evidence: Moderate).

References

1 De Porras-Carrique T, Ramos-García P, González-Moles MÁ. Hypertension in oral lichen planus: A systematic review and meta-analysis. Oral diseases 2024. link 2 Zhang Y, Mao C, Zhu J, Yu W, Wang Z, Wang Y et al.. Effect of platelet concentrates for pain and symptom management in oral lichen planus: an evidence-based systematic review. BMC oral health 2023. link 3 Rezazadeh F, Haghighat S. Serum Vitamin Profile in Oral Lichen Planus Patients in Southwest of Iran. BioMed research international 2021. link 4 Alqahtani M, Woods TR, Smith MH, Bhattacharyya I, Cohen DM, Islam MN et al.. Medication use and medical history of 155 patients with oral lichenoid lesions: a retrospective study. General dentistry 2018. link 5 Sanketh DS, Srinivasan SR, Patil S, Ranganathan K. Issues related to diagnosing oral lichen planus among oral pathologists in South India: A pilot survey. Journal of investigative and clinical dentistry 2017. link 6 Paulusová V, Rösch C, Drízhal I, Perlík F, Masín V, Sukumar S et al.. Cytochrome P450 2D6 polymorphism and drug utilization in patients with oral lichen planus. Acta odontologica Scandinavica 2010. link 7 Kragelund C, Hansen C, Reibel J, Nauntofte B, Brosen K, Jensen SB et al.. Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2010. link 8 Kragelund C, Thomsen CE, Bardow A, Pedersen AM, Nauntofte B, Reibel J et al.. Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes. Oral diseases 2003. link

Nonerosive lichen planus of oral mucosa